Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

被引：0
|
作者：
Lalani, Aly-Khan A.
Swaminath, Anand
Pond, Gregory Russell
Morgan, Scott C.
Azad, Arun
Chu, William
Kapoor, Anil
Bonert, Michael
Bramson, Jonathan L.
Surette, Michael G.
Bosse, Dominick
Siva, Shankar
Bjarnason, Georg A.
Gopaul, Darin
Basappa, Naveen S.
Wright, Jim
Hotte, Sebastien J.
机构：
[1] McMaster Univ, Dept Oncol, Juravinski Canc Ctr, Hamilton, ON, Canada
[2] McMaster Univ, Ontario Clin Oncol Grp, Hamilton, ON, Canada
[3] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[4] Peter MacCallum Canc Ctr, Div Med Oncol, Melbourne, Vic, Australia
[5] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[6] McMaster Univ, St Josephs Healthcare, Hamilton, ON, Canada
[7] St Josephs Healthcare Hamilton, Dept Pathol, Hamilton, ON, Canada
[8] McMaster Immunol Res Ctr, Dept Pathol & Mol Med, Hamilton, ON, Canada
[9] McMaster Univ, Farncombe Family Digest Hlth Res Inst, Hamilton, ON, Canada
[10] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia
[11] Grand River Hosp, Kitchener, ON, Canada
[12] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS750
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
    Lalani, Aly-Khan A.
    Swaminath, Anand
    Pond, Gregory Russell
    Morgan, Scott Carlyle
    Azad, Arun
    Chu, William
    Winquist, Eric
    Kapoor, Anil
    Bonert, Michael
    Bramson, Jonathan L.
    Surette, Michael G.
    Canil, Christina M.
    Siva, Shankar
    Bjarnason, Georg A.
    Levine, Mark Norman
    Wright, Jim
    Hotte, Sebastien J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK)
    Lalani, Aly-Khan A.
    Swaminath, Anand
    Pond, Gregory Russell
    Kapoor, Anil
    Chu, William
    Bramson, Jonathan L.
    Surette, Michael G.
    Levine, Mark Norman
    Hotte, Sebastien J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)
    Chen, Inna M.
    Johansen, Julia S.
    Theile, Susann
    Hjaltelin, Jessica X.
    Novitski, Sif, I
    Brunak, Soren
    Hasselby, Jane P.
    Willemoe, Gro L.
    Lorentzen, Torben
    Madsen, Kasper
    Jensen, Benny, V
    Wilken, Eva E.
    Geertsen, Poul
    Behrens, Claus
    Nolsoe, Christian
    Hermann, Kirstine L.
    Svane, Inge Marie
    Nielsen, Dorte
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (27) : 3180 - +
  • [4] Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC)
    Chen, Inna Markovna
    Johansen, Julia S.
    Theile, Susann
    Hjaltelin, Jessica X.
    Novitski, Sif I.
    Brunak, Soren
    Hasselby, Jane P.
    Willemoe, Gro L.
    Lorentzen, Torben
    Madsen, Kasper
    Jensen, Benny V.
    Wilken, Eva E.
    Geertsen, Poul F.
    Behrens, Claus
    Nolsoe, Christian
    Hermann, Kirstine L.
    Svane, Inge Marie
    Nielsen, Dorte
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [5] Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma
    Weber, J. S.
    Muramatsu, T.
    Hamid, O.
    Mehnert, J.
    Hodi, F. S.
    Krishnarajapet, S.
    Malatyali, S.
    Buchbinder, E.
    Goldberg, J.
    Sullivan, R.
    Faries, M.
    Mehmi, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S869 - S869
  • [6] Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer
    Hannan, Raquibul
    Christensen, Michael
    Hammers, Hans
    Christie, Alana
    Paulman, Brendan
    Lin, Dandan
    Garant, Aurelie
    Arafat, Waddah
    Courtney, Kevin
    Bowman, Isaac
    Cole, Suzanne
    Sher, David
    Ahn, Chul
    Choy, Hak
    Timmerman, Robert
    Brugarolas, James
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (02): : 216 - 224
  • [7] A phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naive metastatic Kidney cancer: the BIONIKK trial
    Elaidi, R. T.
    Oudard, S.
    Braychenko, E.
    Sun, C-M.
    Sautes-Fridman, C.
    Vano, Y-A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC -X Trial).
    Gonzalez, Maria
    Hong, Angela M.
    Carlino, Matteo S.
    Atkinson, Victoria
    Wang, Wei
    Lo, Serigne
    Brown, Michael Paul
    Foote, Matthew C.
    Pinkham, Mark B.
    Le, Hien
    Roos, Daniel E.
    Osorio, Monica
    Haghighi, Neda
    Kok, David
    Postow, Michael A.
    McArthur, Grant A.
    Menzies, Alexander M.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC
    Decker, Roy
    Goldberg, Sarah
    Nath, Sameer
    Husain, Zain
    Lilenbaum, Rogerio
    Schalper, Kurt
    Chiang, Anne
    Altan, Mehmet
    Zelterman, Daniel
    Kaech, Susan
    Herbst, Roy
    Gettinger, Scott
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1303 - S1304
  • [10] Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: Results and toxicity
    Ernst-Stecken, Antje
    Ganslandt, Oliver
    Lambrecht, Ulrike
    Sauer, Rolf
    Grabenbauer, Gerhard
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 (01) : 18 - 24
12345